Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.38 |
| ▸ | PTGIR | P43119 | 2/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100854 | 1.00 | MAPT (0.41) | MAPTUCHL3ALDH1A1TRPA1HPGD | |
| SCHEMBL4111896 | 0.83 | PTGER4 (0.57) | ALDH1A1HPGDMEN1LMNAKMT2A | |
| SCHEMBL4111899 | 0.83 | PTGER4 (0.57) | ALDH1A1HPGDMEN1LMNAKMT2A | |
| SCHEMBL4112690 | 0.83 | ALDH1A1 (0.57) | MAPTUCHL3ALDH1A1HPGDMEN1 | |
| SCHEMBL4112689 | 0.83 | ALDH1A1 (0.57) | MAPTUCHL3ALDH1A1HPGDMEN1 | |
| SCHEMBL4192872 | 0.81 | ALDH1A1 (0.46) | MAPTUCHL3ALDH1A1HPGDMEN1 | |
| SCHEMBL4192876 | 0.81 | ALDH1A1 (0.46) | MAPTUCHL3ALDH1A1HPGDMEN1 | |
| SCHEMBL3985006 | 0.81 | HPGD (0.48) | MAPTUCHL3ALDH1A1TRPA1HPGD | |
| SCHEMBL3985008 | 0.81 | HPGD (0.48) | MAPTUCHL3ALDH1A1TRPA1HPGD | |
| SCHEMBL3992485 | 0.79 | PTGFR (0.55) | ALDH1A1HPGDMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009065081-A2 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124695-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124695-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | PTGER1, PTGER4, PTGER2 | MAPT 4056/4885UCHL3 3759/4885ALDH1A1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.